{"denoms":[{"counts":[{"groupId":"BG000","value":"292"},{"groupId":"BG001","value":"411"},{"groupId":"BG002","value":"422"},{"groupId":"BG003","value":"1125"}],"units":"Participants"}],"groups":[{"description":"Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Not randomized to either adjuvant TMZ arm.","id":"BG000","title":"No Adjuvant TMZ (Not Randomized )"},{"description":"Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.","id":"BG001","title":"Conventional Adjuvant TMZ"},{"description":"Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.","id":"BG002","title":"Dose-dense Adjuvant TMZ"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"22","upperLimit":"87","value":"60.5"},{"groupId":"BG001","lowerLimit":"22","upperLimit":"84","value":"57"},{"groupId":"BG002","lowerLimit":"21","upperLimit":"84","value":"58"},{"groupId":"BG003","lowerLimit":"21","upperLimit":"87","value":"58"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"172"},{"groupId":"BG002","value":"185"},{"groupId":"BG003","value":"483"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"166"},{"groupId":"BG001","value":"239"},{"groupId":"BG002","value":"237"},{"groupId":"BG003","value":"642"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Eligible patients who were randomized."}